Somaxon Pharmaceuticals — Investor Presentation (May 2011)
18 slides from Somaxon Pharmaceuticals's investor presentation, May 24, 2011
Slide 1: SOMX Investor Relations Presentation
SOMX Investor Relations Presentation Rich Pascoe President & CEO Tran Nguyen SVP & CFO May 2011 (r)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about our business, including our commercialization plans and outlook, future financial results and events that have not yet occurred. Operating in the pharmaceutical industry inherently involves significant risks and u
Slide 3: Building Shareholder Value by Executing our Corporate Objectives
Building Shareholder Value by Executing our Corporate Objectives 3 Our goal is to become a leading specialty pharmaceutical company dedicated to creating value for our shareholders through maximizing the potential of our marketed product Silenor(r) and commercializing promising products that treat i
Slide 4: Somaxon Pharmaceuticals Today
Somaxon Pharmaceuticals Today Focused specialty pharmaceutical company Branded prescription products Established commercial organization Flexible and scalable Silenor: Highly differentiated product with meaningful revenue potential First and only non-scheduled Rx sleep maintenance insomnia treatment
Slide 5: Recent Somaxon Developments
Recent Somaxon Developments Continuing to contract with managed care plans to solidify broad patient access Contracted with commercial health plans to ensure unrestricted access for ~110mm lives Tier 2 unrestricted: Medco Health Tier 3 unrestricted: Express Scripts and RxSolutions Providing elderly
Slide 6: Silenor: First-Line Therapy for Sleep Maintenance Insomnia
Silenor: First-Line Therapy for Sleep Maintenance Insomnia First and only FDA-approved product for sleep maintenance insomnia that is not associated with risk of abuse or physical dependence Marketed in U.S. since September 20, 2010 Differentiated insomnia product Potent H1 antagonist1,2 Promotes sl
Slide 7: Insomnia is a Large and Accessible Market
Insomnia is a Large and Accessible Market* Large and growing market $2bn in U.S. sales (2010) 71mm U.S. TRx's (2010) Concentrated market <50,000 doctors write half the TRx's 30% of highest prescribing doctors are specialists Top-decile prescribers average >1,000 Rx's/year Solid "window of opportunit
Slide 8: Primary Issue: Sleep Maintenance
Primary Issue: Sleep Maintenance* * Source: National Sleep Foundation. Summary of findings: 2008 Sleep in America poll. n = 1,760 respondents. Maintenance Onset Difficulty Falling Asleep Frequent Nocturnal Awakenings Early Morning Awakenings Difficulty Falling Asleep 29% 42% 26% 8 Sleep in America p
Slide 9: Silenor: Improved Sleep Efficiency in Adults and the Elderly
Silenor: Improved Sleep Efficiency in Adults and the Elderly* Adults: Sleep Efficiency - Night 1 (35 Night Study, N=221) * Krystal A et al. Sleep. 2010;33(11):1533-1561. Data on file. San Diego, CA: Somaxon Pharmaceuticals, Inc. Elderly: Sleep Efficiency - Night 1 (85 Night Study, N=240) 9 9 * * * *
Slide 10: Silenor: Adverse Events in Controlled Studies
Silenor: Adverse Events in Controlled Studies 10 Adverse Event* Placebo (N=278) Silenor 3mg (N=157) Silenor 6mg (N=203) Nervous System Disorders Somnolence/Sedation 4% 6% 9% Infections and Infestations Upper Respiratory Tract Infection/Nasopharyngitis 2 4 2 Gastroenteritis 0 2 0 Gastrointestinal Dis
Slide 11: Silenor Commercial Strategy
Silenor Commercial Strategy Target high-value physicians through experienced sales force Establish strong market share within targeted physicians Non-personal promotion to physicians Increase frequency with targeted physicians Broaden reach to non-targeted physicians Partnered with leading professio
Slide 12: Highly Leverageable Commercial Organization
Highly Leverageable Commercial Organization Combined 250 sales reps Target 40,000 high-valued physicians 1Q 2011 sales force metrics >90,000 details to physicians* >10,000 calls to pharmacies* >280,000 sample packs distributed* Somaxon's 145 sales reps to call on ~23,000 high-value physicians Specia
Slide 13: Current Silenor Patient Coverage Distribution
Current Silenor Patient Coverage Distribution* Currently ~200mm commercial lives have access to reimbursement for Silenor Contracted unrestricted access for ~110mm lives: Medco (T2): 37mm CVS/Caremark (T3): 52mm Express Scripts (T3): 14mm RxSolutions (T3): 3mm Blue Shield of CA (T3): 3mm Prime Thera
Slide 14: Recent April 2011 Refill Rate at 27%
14 Recent April 2011 Refill Rate at 27% * Normalized to account for 33 tablets per prescription due to mail order prescriptions. Silenor Prescriptions: Over 40,000 TRx* Since Launch (CHART)
Slide 15: Silenor: Patent Coverage
Silenor: Patent Coverage 15 Orange Book Listed Patents Orange Book Listed Patents Orange Book Listed Patents Orange Book Listed Patents Patent Number Issue Date Expiration Date 1. Method of use (food effect) 7,915,307 03/29/11 08/24/27 2. Method of use (transient) 6,211,229 04/03/01 02/17/20 3. Meth
Slide 16: Financials Summary Information
Financials 16 Summary Information Actual Cash, cash equivalents & marketable securities (3/31/11) $43.3mm Shares outstanding 45.0mm Fully diluted shares1 52.6mm Other Information Comment(s) Full-Year 2011 total OpEx guidance $78-83mm (includes $4mm of non-cash, share-based compensation expense)$74-7
Slide 17: Somaxon Investment Highlights
Somaxon Investment Highlights Silenor Highly differentiated sleep maintenance insomnia treatment Potential to generate meaningful near and long-term revenue Strong IP position; Latest patent expires in 2027 Somaxon maintains full ownership of asset and strategic autonomy Significant growth potential
Slide 18: SOMX Investor Relations Presentation
SOMX Investor Relations Presentation Rich Pascoe President & CEO Tran Nguyen SVP & CFO May 2011 (r)
Somaxon Pharmaceuticals — Investor Presentation (May 2011) on 6ix